Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 2
2005 5
2006 17
2007 13
2008 14
2009 6
2010 12
2011 8
2012 9
2013 12
2014 5
2015 11
2016 6
2017 3
2018 2
2019 1
2021 4
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Chi KN, et al. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. J Clin Oncol. 2023. PMID: 36952634 Free PMC article. Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL; CIMBA Consortium; Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porte… See abstract for full author list ➔ Rebbeck TR, et al. Among authors: byrski t. JAMA. 2015 Apr 7;313(13):1347-61. doi: 10.1001/jama.2014.5985. JAMA. 2015. PMID: 25849179 Free PMC article.
Systemic treatment for hereditary cancers: a 2012 update.
Imyanitov EN, Byrski T. Imyanitov EN, et al. Among authors: byrski t. Hered Cancer Clin Pract. 2013 Apr 1;11(1):2. doi: 10.1186/1897-4287-11-2. Hered Cancer Clin Pract. 2013. PMID: 23548133 Free PMC article.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Selenium as marker for cancer risk and prevention.
Lener M, Jaworska K, Muszyńska M, Sukiennicki G, Durda K, Gupta S, Złowocka-Perłowska E, Kładny J, Wiechowska-Kozłowska A, Grodzki T, Jaworowska E, Lubiński J, Górecka-Szyld B, Wilk G, Sulikowski M, Huzarski T, Byrski T, Cybulski C, Gronwald J, Dębniak T, Ashuryk O, Tołoczko-Grabarek A, Jakubowska A, Morawski A, Lubiński J. Lener M, et al. Among authors: byrski t. Pol Przegl Chir. 2012 Sep;84(9):470-5. doi: 10.2478/v10035-012-0080-6. Pol Przegl Chir. 2012. PMID: 23241574 Review. No abstract available.
Selenium as a marker of cancer risk and of selection for control examinations in surveillance.
Lener M, Muszyńska M, Jakubowska A, Jaworska-Bieniek K, Sukiennicki G, Kaczmarek K, Durda K, Gromowski T, Serrano-Fernández P, Kładny J, Wiechowska-Kozłowska A, Grodzki T, Jaworowska E, Lubiński J, Górecka-Szyld B, Wilk G, Huzarski T, Byrski T, Cybulski C, Gronwald J, Dębniak T, Ashuryk O, Tołoczko-Grabarek A, Morawski A, Scott RJ, Lubiński J. Lener M, et al. Among authors: byrski t. Contemp Oncol (Pozn). 2015;19(1A):A60-1. doi: 10.5114/wo.2014.47131. Contemp Oncol (Pozn). 2015. PMID: 25691823 Free PMC article. Review.
Hereditary breast and ovarian cancer.
Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymanska-Pasternak J, Górski B, Menkiszak J, Rzepka-Górska I, Lubinski J. Gronwald J, et al. Among authors: byrski t. Hered Cancer Clin Pract. 2008 Jun 15;6(2):88-98. doi: 10.1186/1897-4287-6-2-88. Hered Cancer Clin Pract. 2008. PMID: 19804604 Free PMC article. No abstract available.
Germline RECQL mutations are associated with breast cancer susceptibility.
Cybulski C, Carrot-Zhang J, Kluźniak W, Rivera B, Kashyap A, Wokołorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Rudnicka H, Lener M, Masojć B, Tonin PN, Rousseau F, Górski B, Dębniak T, Majewski J, Lubiński J, Foulkes WD, Narod SA, Akbari MR. Cybulski C, et al. Among authors: byrski t. Nat Genet. 2015 Jun;47(6):643-6. doi: 10.1038/ng.3284. Epub 2015 Apr 27. Nat Genet. 2015. PMID: 25915596
117 results